Stamford, Connecticut-based SpringWorks' Gomekli (mirdametinib) has become the first medicine approved for both adults and children with plexiform neurofibromas (PN) in patients with the genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback